MAPT and Alzheimer disease: Clinically accessible tests, such as positron emission tomography (PET) scans, could mitigate the number of misdiagnoses; however, even fluorodeoxyglucose PET scans can be normal in early bvFTD [36], and amyloid or tau PET imaging are not readily or economically available for AD.